Patrick Wood

“One, just the State of the Union on the smart care business, like the Sarah and Care AI. I know, obviously, it was last quarter, but that's been a big push this year, so that's the first one.”

“The generic injectables business, obviously, there's a lot going on there in general. You know, one of your peers also has a warning letter. Some of us remember what happened in the 20 teens with drug shortages.”

“You know, from my perspective, taking a step back, I mean, the numbers, obviously, you guys crushed it. Margins, growth, pretty much across the piece. Clearly, you know, the strategy has been working well, and I'd love to hear more about that.”

“Thank you so much for the question i really appreciate it um i'd love to start on the pipeline and really just dig into that because obviously you know you've got conduction system pacing midterm and the 360 you know probably 200 billion of biologic drugs going through loe there's obviously a lot midterm that's going…”

“Were you guys surprised by the incremental pump shipments following Instinct? I mean, you mentioned the UK and that side of things. And I guess the way I'm sort of thinking about it is looking forward and thinking about Flex, Vivera and everything else like that.”